News

PHA Honors 7 Outstanding Community Members at Conference

Seven members of the pulmonary hypertension (PH) community — ranging from an 11-year-old advocate diagnosed in infancy to a physician who has led clinical trials, to a longtime fundraiser who’s a retired teacher — have been honored for their dedication and service by the Pulmonary Hypertension Association (PHA).

Sotatercept Could Be Effective PAH Treatment, Rodent Models Suggest

Treatment with an analog of sotatercept, Acceleron Pharma’s experimental therapy, eased disease-associated inflammation and changes in blood vessel architecture in multiple rodent models of pulmonary arterial hypertension (PAH), a study reported. The study, “Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension,” was published in…

Inhaled Seralutinib Shows Promise in 2 PAH Animal Models

Seralutinib (GB002), an investigational inhaled treatment for pulmonary arterial hypertension (PAH), effectively treated severe disease in two animal models, a study demonstrated. Further, when compared directly, inhaled seralutinib showed greater efficacy than imatinib, an approved cancer therapy also being investigated for PAH. Gossamer Bio, seralutinib’s developer, now is testing…

Sacubitril-Valsartan Eases PH in Some Heart Failure Patients

Sacubitril-valsartan — a combination oral therapy approved to treat heart failure — rapidly reduces pulmonary blood pressure in people with pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF), according to data from a Phase 3 clinical trial. Notably, these benefits were accompanied by reduced lung…

High Rate of Hospitalization, Mortality With COVID-19: Study

People with pulmonary hypertension (PH) who were diagnosed with COVID-19 had a high rate of hospitalization and in-hospital mortality, a French study concluded. Risk factors for adverse outcomes included being older, male, having co-existing conditions, or comorbidities, and having more severe PH. Anticoagulants (blood thinners) were the only treatment…

Lowering Pulmonary Blood Pressure Linked to Better Survival in Study

A mean pulmonary artery pressure (mPAP) — blood pressure in the lungs — of less than 40 mmHg (millimeters of mercury) significantly increases the survival rate of patients with different subsets of pulmonary arterial hypertension (PAH), a study suggests. The successful outcome was achieved with an intensive therapeutic approach…